Rilutek (riluzole) vs Lunasin (lunasin)

Rilutek (riluzole) is an FDA-approved medication specifically indicated for the treatment of amyotrophic lateral sclerosis (ALS), and it works by reducing the release of glutamate, which is thought to be related to the pathology of ALS. Lunasin, on the other hand, is a peptide that is being studied for its potential health benefits, including anti-inflammatory and antioxidant properties, but it is not a medication and is not approved by the FDA for the treatment of ALS or any other specific disease. When deciding between Rilutek and Lunasin for medical treatment, it is crucial to consult with a healthcare provider, as Rilutek is the only one of the two that is an established pharmaceutical treatment for a specific condition, whereas Lunasin is considered a supplement and lacks robust clinical evidence for the treatment of diseases.

Difference between Rilutek and Lunasin

Metric	Rilutek (riluzole)	Lunasin (lunasin)
Generic name	Riluzole	Lunasin
Indications	Amyotrophic lateral sclerosis (ALS)	Not FDA approved for specific indications; researched for potential benefits in cancer, cardiovascular diseases, and neurodegenerative disorders
Mechanism of action	Reduces glutamate release, which may protect neurons from excitotoxicity	May inhibit histone acetyltransferase, which can influence gene expression and have anti-inflammatory, antioxidant, and potentially anticancer effects
Brand names	Rilutek, Teglutik	Not available as a pharmaceutical brand; sold as a dietary supplement
Administrative route	Oral	Oral
Side effects	Dizziness, gastrointestinal disturbances, liver function alterations	Generally well tolerated; limited data on side effects
Contraindications	Liver disease, caution in patients with renal impairment	Insufficient data to determine specific contraindications
Drug class	Glutamate antagonist	Not classified as a drug; considered a bioactive peptide
Manufacturer	Sanofi	Various dietary supplement manufacturers

Efficacy

Rilutek (Riluzole) and Its Efficacy in ALS

Rilutek, known generically as riluzole, is a medication specifically approved by the FDA for the treatment of Amyotrophic Lateral Sclerosis (ALS). ALS, also known as Lou Gehrig's disease, is a progressive neurodegenerative condition that affects nerve cells in the brain and spinal cord, leading to loss of muscle control. Riluzole is believed to reduce damage to motor neurons by decreasing the release of glutamate, which could otherwise be toxic to the neurons in high concentrations.

Clinical trials have demonstrated that Rilutek can extend survival in ALS patients by several months. It has shown a modest effect on prolonging the time before a patient needs ventilation support. However, Rilutek does not reverse the damage already done to motor neurons, and its impact on muscle strength and neurological function is limited. The medication's efficacy varies among individuals, and it is typically more effective when administered in the early stages of the disease.

Lunasin and Its Potential Role in ALS

Lunasin is a peptide that has been studied for its potential health benefits, including anti-inflammatory and antioxidant properties. While it is not approved by the FDA for the treatment of ALS, some preclinical studies and anecdotal evidence have suggested that lunasin might have a role in modifying the progression of ALS. Lunasin is thought to work by modulating the expression of certain genes and reducing inflammation, which could be beneficial in neurodegenerative diseases like ALS.

However, the evidence for lunasin's efficacy in ALS is not as robust as for Rilutek. Clinical data on lunasin's effects on ALS are limited, and more research is needed to establish its safety and effectiveness. As of the current knowledge cutoff, there have been no large-scale, randomized controlled trials to conclusively determine the benefits of lunasin in ALS patients. Therefore, while lunasin may hold promise, it is not currently recognized as a standard treatment for ALS, and its use should be considered experimental.

Regulatory Agency Approvals

Rilutek

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Therapeutic Goods Administration (TGA), Australia
Medicines & Healthcare products Regulatory Agency (MHRA), United Kingdom
Medsafe (NZ)

Lunasin

Food and Drug Administration (FDA), USA

Access Rilutek or Lunasin today

If Rilutek or Lunasin are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Rilutek

Buy Lunasin

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: